Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Eurofins Technologies

Eurofins Technologies, part of the Eurofins Scientific group, is a fast-growing, global provider of diagnostic test k... read more Featured Products: More products

Download Mobile App





Eurofins Launches New Multiplex PCR Assay for Rapid Detection of B.1.617 Kappa SARS-CoV-2 Variant

By LabMedica International staff writers
Posted on 04 Jun 2021
Eurofins Technologies (Ebersberg, Germany) has launched its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including B.1.617 (India), B.1.427/B.1.429 (California/USA), B.1.351 (South Africa) or P.1 (Brazil).

The assay facilitates the identification of the relevant mutations E484Q, E484K and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 wildtype variant. More...
These mutations have been associated with reports of potential decreased efficacy of certain vaccines and an increase in the transmissibility of the virus.

GSD NovaType III SARS-CoV-2 is the latest addition to the GSD NovaType product line, a continuously updated panel of single and multiplex assays for the screening and detection of emerging Variants of Concern (VOC) and of Interest (VOI) on positive samples. These assays may play an important role in the fight against COVID-19 by enabling the rapid identification of new variants that may endanger the success of global vaccination campaigns and the implementation of enhanced isolation, testing and vaccination measures in affected areas. GSD NovaType III SARS-CoV-2 will be available as a research-use-only kit by the June 9. A CE marked version is expected by the second half of June.




Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Portable Electronic Pipette
Mini 96
8-Channel Pipette
SAPPHIRE 20–300 µL
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.